$12.48
+0.81%Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CTNM • NASDAQ
| Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-60M | -42.3M | 22.7M | -24.3M | -29M | |
323K | 258K | 195K | 329K | 325K | |
10M | 6.8M | 2.2M | 1.9M | 1.7M | |
344K | -3M | -4.8M | 3.1M | 553K | |
(0.0) | (0.0) | (450K) | (0.0) | (0.0) | |
-6M | 5.3M | -1M | -1.3M | 108K | |
-55.3M | -32.8M | 19.3M | -20.1M | -26.3M | |
INVESTING ACTIVITIES | |||||
-231K | -514K | -414K | -118K | -168K | |
(0.0) | (20K) | (0.0) | (0.0) | (0.0) | |
-162.5M | -226.4M | -141.9M | -64.7M | -66.8M | |
159M | 157.2M | 76.7M | 87.1M | 2M | |
-3.7M | -69.7M | -65.6M | (22.3M) | -65M | |
FINANCING ACTIVITIES | |||||
112.7M | 108.2M | -28K | -4K | 0.0 | |
0.0 | 0.0 | -3.8M | -1.3M | 0.0 | |
(0.0) | (0.0) | -28K | -4K | (0.0) | |
0.0 | 790K | -184K | 15K | 113K | |
112.7M | 109M | 56.2M | -1.2M | 79.8M | |
CASH FLOW SUMMARY | |||||
53.7M | 6.4M | 10M | 939K | -11.4M | |
21.9M | 15.5M | 5.6M | 4.6M | 16M | |
75.6M | 21.9M | 15.5M | 5.6M | 4.6M | |
-55.5M | -33.4M | 18.9M | -20.2M | -26.4M |
CTNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 23, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 20, 2025 | 2025 |
Continue your CTNM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.